Kilitch Drugs (India) (NSE:KILITCH) Common Stock: ₹350 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:KILITCH Kilitch Drugs (India) Ltd NSE:KILITCH
84 GF Score
Price ₹182.75
GF Value ₹226.73
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Kilitch Drugs (India) Common Stock?

Kilitch Drugs (India) NSE:KILITCH +1.28% 84 Common Stock is ₹350 Mil as of Mar. 2026. GuruFocus rates NSE:KILITCH with a GF Score™ of 84/100 and a GF Value™ of ₹226.73 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Kilitch Drugs (India)'s quarterly common stock declined from Sep. 2025 (₹175 Mil) to Dec. 2025 (₹0 Mil) but then increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹350 Mil).

Kilitch Drugs (India)'s annual common stock stayed the same from Mar. 2024 (₹161 Mil) to Mar. 2025 (₹161 Mil) but then increased from Mar. 2025 (₹161 Mil) to Mar. 2026 (₹350 Mil).

Kilitch Drugs (India) Common Stock Historical Data

* Premium members only.

The historical data trend for Kilitch Drugs (India)'s Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kilitch Drugs (India) Common Stock Chart

Kilitch Drugs (India) Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 155.82 155.82 160.82 160.82 349.62

Kilitch Drugs (India) Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 160.82 0.00 174.81 0.00 349.62
NSE:KILITCH
84GF Score
Kilitch Drugs (India) Ltd NSE:KILITCH
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kilitch Drugs (India) Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of ₹350 Mil mean?
Kilitch Drugs (India) (NSE:KILITCH) has a Common Stock of ₹350 Mil as of Mar. 2026. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Kilitch Drugs (India) and its competitors.
Is Kilitch Drugs (India)'s Common Stock too high?
Kilitch Drugs (India)'s current Common Stock is ₹350 Mil. Overall, Kilitch Drugs (India) has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kilitch Drugs (India)'s Common Stock compare to ZTS and UTHR?
Kilitch Drugs (India)'s Common Stock of ₹350 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Drug Manufacturers company?
A good Common Stock depends on the Drug Manufacturers industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Kilitch Drugs (India) and its competitors. Kilitch Drugs (India)'s current Common Stock is ₹350 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kilitch Drugs (India) stock overvalued right now?
Based on GuruFocus' analysis, Kilitch Drugs (India) (NSE:KILITCH) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹226.73, compared to a current price of ₹182.75 — trading 19.4% below its estimated fair value. The current Common Stock is ₹350 Mil. Kilitch Drugs (India)'s overall GF Score™ is 84/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Kilitch Drugs (India) (NSE:KILITCH), the current Common Stock is ₹350 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kilitch Drugs (India) (NSE:KILITCH) Overvalued in 2026?

Based on GuruFocus' analysis, Kilitch Drugs (India) stock appears to be undervalued. The current stock price of ₹182.75 is trading 19.4% below its estimated GF Value™ of ₹226.73. GuruFocus considers Kilitch Drugs (India) to be Modestly Undervalued.

Key valuation signals for NSE:KILITCH:

  • Common Stock: ₹350 Mil
  • GF Value™: ₹226.73 vs. price of ₹182.75 (19.4% below fair value)
  • GF Score™: 84/100 with 4 warning signs

No single metric tells the full story. See the NSE:KILITCH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kilitch Drugs (India) Business Description

Other Exchanges 524500:India
Address Waman Tukaram Patil Marg, 37/39, Ujagar Industrial Estate, Deonar, Mumbai, MH, IND, 400 088
Kilitch Drugs (India) Ltd is an India-based pharmaceutical company. It is engaged in operation and management of Pharmaceutical Products. The company offers parenteral and nasal products, oral formulations, effervescent tablets, nutritional products, medical devices, and cosmetic and health products. Some of the products offered by the company are Roipar, Roivit, PH-7, C-Seal, SRO kit, 9-VIT, and HPURE. The company has one reportable segment, which is the development and operations of the Pharmaceutical business.
84GF Score

Get the complete analysis for NSE:KILITCH

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹182.75
Price
₹226.73
GF Value